Genomic Cancer Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Genomic Cancer Testing Market is projected to expand from USD 14.48 Billion in 2025 to USD 26.37 Billion by 2031, reflecting a CAGR of 10.51%. This market consists of diagnostic solutions designed to examine genetic mutations in tumor DNA, thereby guiding personalized oncology treatments. A primary driver for this sector is the broad acceptance of precision medicine combined with a critical increase in cancer incidence rates that necessitate accurate molecular profiling. Data from the American Cancer Society indicates that 2,001,140 new cancer cases are expected in the United States in 2024, highlighting the escalating disease burden that fuels the need for advanced diagnostic interventions and targeted therapies.

Technological adoption further bolsters market growth by facilitating the simultaneous detection of multiple mutations, which streamlines the decision-making process for therapeutics. Providers are increasingly prioritizing these detailed insights to improve patient survival rates through customized care plans. However, the industry encounters a major hurdle regarding inconsistent reimbursement frameworks and high implementation expenses, which continue to obstruct equitable access and restrict market expansion across healthcare systems that are sensitive to costs.

Market Drivers

The incorporation of Artificial Intelligence into Genomic Analysis is transforming the speed and precision of tumor profiling by directly managing the data complexity associated with next-generation sequencing. By utilizing machine learning algorithms, laboratories can interpret massive genomic datasets more effectively, pinpointing rare mutations and therapeutic targets that conventional methods might overlook. This technological synergy drives significant commercial growth as providers enhance their diagnostic capabilities; for instance, Tempus AI reported in its 'Q3 2025 Quarterly Report' (November 2025) a net revenue of $334.2 million, an 85% year-over-year increase largely attributed to its AI-enabled data and genomics services, underscoring the vital role of computational power in scaling precision oncology.

Simultaneously, the growing preference for Non-Invasive Liquid Biopsy is widening market access by providing a patient-friendly alternative to tissue sampling. These blood-based tests enable continuous monitoring of treatment responses and early recurrence detection without the risks linked to surgical biopsies, a shift reflected in rising test volumes. Guardant Health’s 'Third Quarter 2025 Financial Results' (October 2025) noted a 40% year-over-year increase in oncology test volume to approximately 74,000 tests. This adoption is crucial for managing global healthcare demand, as The ASCO Post (October 2025), citing 'The Cancer Atlas, 4th Edition', projects the global cancer burden will rise by roughly 74% from 2022 to 2050 to 33 million new annual cases, necessitating scalable solutions like liquid biopsy.

Market Challenges

High implementation costs and inconsistent reimbursement policies constitute a primary restraint on the growth of the Global Genomic Cancer Testing Market. Insurers often categorize comprehensive genomic profiling as experimental or medically unnecessary, leading to coverage denials that impose a severe financial strain on patients. When reimbursement pathways are restrictive or unclear, clinical laboratories struggle to recover the significant capital invested in these tests, and physicians are deterred from ordering diagnostics that patients cannot afford. This economic misalignment reduces the volume of processed tests and limits market penetration, especially in regions with cost-conscious healthcare infrastructures.

Administrative hurdles further amplify the impact of these financial barriers by delaying or blocking access to care. According to the American Medical Association, 78% of physicians in 2024 reported that prior authorization policies frequently resulted in patients abandoning recommended tests or treatments. This high rate of test abandonment illustrates how restrictive payer policies directly diminish market revenue. Consequently, without consistent coverage, the adoption of genomic testing remains largely confined to well-funded academic centers, hindering the broader expansion required for sustained market growth.

Market Trends

The decentralization of Next-Generation Sequencing to in-house clinical labs is fundamentally reshaping the market by allowing hospitals to perform genomic testing on-site. While complex molecular profiling was historically outsourced to reference laboratories - often causing delays - the availability of regulatory-approved kitted solutions and user-friendly desktop sequencers now empowers local institutions to conduct comprehensive profiling internally for immediate data access. This shift toward local adoption is driving significant consumption of clinical sequencing reagents; Illumina’s 'Third Quarter 2024 Financial Results' (November 2024) reported a 7% year-over-year increase in sequencing consumables revenue to $741 million, attributed to the rising clinical utilization of their platforms in hospital settings.

In parallel, the proliferation of Companion Diagnostic (CDx) collaborations is strengthening the connection between pharmaceutical development and diagnostic testing. Drug developers are increasingly partnering with diagnostic firms during early clinical trials to co-develop validated assays, ensuring that novel targeted therapies are launched with ready-to-use biomarker tests. This collaborative model accelerates patient identification and maximizes the immediate clinical uptake of new drugs. The commercial impact is significant, as evidenced by Qiagen’s 'Q3 2024 Financial Results' (November 2024), where sales in the Diagnostic Solutions group rose 10% at constant exchange rates, a performance explicitly driven by the expansion of partnerships for companion diagnostic co-development.

Key Players Profiled in the Genomic Cancer Testing Market

• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN NV
• Merck KGaA
• Abbott Laboratories Inc.
• Novogene Co., Ltd.
• Guardant Health, Inc.
• Personal Genome Diagnostics Inc.
• Thermo Fisher Scientific Inc.
• NeoGenomics Laboratories, Inc.

Report Scope

In this report, the Global Genomic Cancer Testing Market has been segmented into the following categories:

Genomic Cancer Testing Market, by Test Type:

• Genomic Profiling Tests
• Liquid Biopsy Tests
• Companion Diagnostic Tests
• Pharmacogenomic Tests
• Hereditary Cancer Tests
• Others

Genomic Cancer Testing Market, by Technology:

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescence In Situ Hybridization (FISH)
• Immunohistochemistry (IHC)
• Others

Genomic Cancer Testing Market, by End User:

• Hospitals
• Diagnostic Laboratories
• Academic and Research Institutions
• Cancer Centers
• Others

Genomic Cancer Testing Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genomic Cancer Testing Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.